oncosil MEDICAL ASX.OSL

Bell Potter Healthcare Conference

Path to Commercialisation

26 November 2020

OncoSil Medical is a commercial-stage medical device company

Who are we

- Developing and commercialising its proprietary platform technology, OncoSil™
- OncoSil's first approved indication is in locally advanced pancreatic cancer, with first commercial sale in October 2020
- Filed for humanitarian use indication of bile duct cancer in US

What is our technology

- Proprietary brachytherapy (internal radiation) medical device
- Implanted device (brachytherapy) delivering targeted radiation to pancreatic tumour
- Breakthrough device designation in US, Europe and parts of Australasia

What approvals have we received

- Approved to sell in UK, EU, Switzerland, Singapore, Malaysia and New Zealand
- Awaiting regulatory clearance in Australia and Hong Kong
- CE Mark approval
- Breakthrough designation in US, EU, UK and Singapore
- Patent protected across all key jurisdictions

What our data shows

PanCo trial results

- ✓ Excellent Local Disease Control
- ✓ Higher Disease Control Rate
- ✓ Prolonged Overall Survival
- ✓ Tumour reduction
- ✓ Encouraging rate of Surgical Resection with Curative intent
- ✓ Prolonged Progression Free Survival

Achievements to date in 2020

List of milestones achieved since CE Mark in April 2020

Completed ~$19m placement and entitlement offer to fund commercialisation globally	✓
Appointment of Nigel Lange (ex Sirtex Europe CEO) to drive European commercialisation	✓
Humanitarian Device Exemption (HDE) filing with FDA for Bile Duct Cancer	✓
Regulatory filing in Australia	✓
Regulatory clearance in Singapore, Malaysia and Switzerland	✓
First commercial sale achieved in New Zealand	✓

Status ✓ Yes ✓ In part ✗ No

Upcoming catalysts

- **Targeting first sale in UK/EU** – 2H CY20
- **Regulatory decision in US for Bile Duct Cancer** – anticipated Q4 CY20 (or Q1 CY 21)[1]
- **Regulatory clearance in Australia** – anticipated 1H CY21[2]
- **Regulatory decision in Hong Kong** – anticipated 2H CY20[2]

Notes.

[1] 75 day review subject to FDA process and questions which may delay decision

[2] Subject to Regulatory process and questions which may delay decision timing

Commercialisation update

First commercial sale achieved	First commercial sale for OncoSil achieved, with patient treated in New Zealand on 20 October, marking OncoSil's transition towards being a revenue-generating medical device company
Europe LAPC	Preparation activities well underway (see next page for further details), also recently received approvals in Switzerland where separate registration filing was required
ASEAN / APAC LAPC	Approved to sell in New Zealand (first sales achieved), Singapore and Malaysia; awaiting outcomes of registrations filed in Australia and Hong Kong
US Bile duct cancer	Humanitarian Device Exemption (HDE) application filed with the FDA in July 2020 for the treatment of bile duct cancer; building on OncoSil's dual pronged US market strategy
PanCO update	Compelling results highlighting OncoSil's downstaging significance, with 60% of patients that underwent surgery alive today with a survival range of 26-35 months post-treatment
Cash position	Well capitalised to pursue commercialisation objectives with a cash balance of A$20.5 million as at 30 September 2020

Launch activities in Europe

Sales force and go-to-market activities	✓ 9 direct OncoSil sales force and training resource in place in UK, Germany, Italy, Benelux ✓ Sales force recruitment continues ✓ Progressing both direct sales and distributor agreement strategies
Hospital onboarding	✓ Central Radio-pharmacy (CRP) established & contracted to service up 15 hospital in the Greater London area ✓ Multiple hospitals onboard with site training and certification continuing
Patient registry	✓ OSPREY Patient Registry “operationally ready” to support commercialisation
Training	✓ Authorised Users - Nuclear Medicine Physicians, Interventional Radiologist & Radiation Oncologists: 10 ✓ Authorised Users - Endoscopist: 2 (7 more to be training covering multiple sites) ✓ Authorised Dispensers – Radiation Physicists and Nuclear Medicine Technicians: 25 ✓ Endoscopy Nurses – 5 ✓ Cold Dose Dilutions (CRP): 7

Multi-pronged sales strategy in various regions

Flexibility to pursue either direct sales or distributor agreements in approved regions

Direct salesforce in UK, Germany, Italy, Benelux

Distributor arrangements being finalised in Switzerland, Turkey

Direct salesforce in Singapore and Malaysia

Direct salesforce in Australia & New Zealand

Updated analysis on resected cohort illustrates potential to convert inoperable patients to operable status

42 patients treated

- 42 patients with unresectable, locally advanced pancreatic cancer (uLAPC) enrolled in the PanCO trial
- All patients were initially determined to be inoperable or medically unfit for surgery
- Typically, survival lengths of uLAPC patients is ~8.5 months[1]

All were implanted with the OncoSil™ device

10 underwent surgery

- 14 were sufficiently downstaged to be technically considered for surgical resection
- 4 of these patients were unable to undergo surgery due to co-morbidities or other considerations
- 10 patients subsequently underwent surgery, thus forming the resected cohort sub-group

This leads to a technical resection rate of 33%

6 remain alive with >26 months survival post-treatment

- OncoSil completed an updated analysis in July 2020 on the resected cohort sub-group:
  - Median follow-up of 31.1 months
  - 4 deaths have been reported to date (at 18.8, 20.9, 21.0 and 22.1 months)
  - 60% of patients remain alive today with a survival range of 26-35 months post-treatment

Analysis highlights potential to "convert" previously deemed inoperable patients to operable status

Notes.

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

Investment Highlights

Proven world class technology: OncoSil™ is a unique and innovative platform technology with compelling clinical data for pancreatic cancer treatment - doubling of the median overall survival length and downstaging of previously unresectable patients – Platform technology can be leveraged into other indications (bile duct cancer, liver)

A clear global opportunity: >US$3bn market opportunity to become standard of care in combination with chemotherapy; solving global unmet need for pancreatic cancer patients where surgery is not a viable option

First commercial sale achieved, ready to commercialise globally: Ready to commercialise for launch in Europe, UK and Asia following milestone CE Mark approval and first commercial sale completed in New Zealand in October 2020

Highly attractive and scalable operating model: Strong operating leverage with high gross margins when at scale, with a low fixed cost base - low cost salesforce and a highly scalable manufacturing and distribution capability in place

Best-in-class leadership team: Highly experienced board and management team with successful track record developing, licensing and commercialising early stage drugs

Important notice

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 22 October 2020.

Daniel Kenny
CEO & Managing Director
E: daniel.kenny@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

T: +61 2 9223 3344
F: +61 2 9252 3988

oncosil
MEDICAL